Adolfo  Garcia - Sastre, Ph.D

Adolfo Garcia - Sastre, Ph.D

Mount Sinai School of Medicine

DIRECTOR GLOBAL HEALTH AND EMERGING PATHOGENS INSTITUTE PROFESSOR | MICROBIOLOGY PROFESSOR

Expertise: AntiviralsBiodefenseCellular ImmunityCytokinesisGene ExpressionsGene RegulationGene TherapyVirusesVirologyVaccine Development

Dr. García-Sastre is a Professor in the Department of Microbiology and Director of the Global Health and Emerging Pathogens Institute of Icahn School of Medicine at Mount Sinai in New York. For the past 25 years, his research interest has been focused on the molecular biology of influenza viruses and several other negative-strand RNA viruses. During his post-doctoral training in the early 1990s, he developed, for the first time, novel strategies for expression of foreign antigens by a negative-strand RNA virus, influenza virus. He has made major contributions to the influenza virus field, including 1) the development of reverse genetics techniques allowing the generation of recombinant influenza viruses from plasmid DNA, (studies in collaboration with Dr. Palese); 2) the generation and evaluation of negative-strand RNA virus vectors as potential vaccine candidates against different infectious diseases, including malaria and AIDS, and 3) the identification of the biological role of the non-structural protein NS1 of influenza virus during infection: the inhibition of the type I interferon (IFN) system. His studies provided the first description and molecular analysis of a viral-encoded IFN antagonist among negative-strand RNA viruses.  These studies led to the generation of attenuated influenza viruses containing defined mutations in their IFN antagonist protein that might prove to be optimal live vaccines against influenza. His research has resulted in more than 480 scientific publications and reviews. Dr. García-Sastre is the director of the Center for Research on Influenza Pathogenesis (CRIP), one of the five NIAID funded Centers of Excellence for Influenza Research and Surveillance. He was among the first members of the Vaccine Study Section and member of the Virology B Study Section of NIH. In addition, he has served for 5 years as Editor of Journal of Experimental Medicine, is Editor of PLoS Pathogens, Journal of Virology and Virus Research, and member of the Editorial Board of Virology, Vaccine, NPJ Vaccines and Influenza and Other Respiratory Diseases.  He is a member of the scientific advisory board of Keystone Symposia. He has been a co-organizer of the international course on Viral Vectors (2001), held in Heidelberg, Germany, sponsored by Federation of European Biochemical Societies (FEBS), and of the first Research Conference on Orthomyxoviruses in 2001, held in Texel, The Netherlands, sponsored by the European Scientific Working Group on Influenza (ESWI). He has also been a co-organizing of the 7th International Society for Vaccines meeting in 2013, and of Keystone Meetings in 2014 on Respiratory Virus Pathogenesis and in 2017 on Interferons. His publication in Science on the reconstruction and characterization of the pandemic influenza virus of 1918 has been awarded the distinction of the paper of the year 2005 by Lancet. In 2005, he became a Fellow of the American Academy of Microbiology, and in 2009, he received the Beijerink Professorship from the National Academy of Sciences of the Netherlands. In 2011, he has been elected President of the International Society for Vaccines, for 2014 and 2015. In 2017, he has been elected a fellow of the Royal Academy of Pharmacy in Spain.

Title

Cited By

Year

Mount Sinai Researcher Receives NIH Award to Study Immune Responses of Patients With Inflammatory Skin Diseases in the Setting of COVID-19 Infection

The study will aim to understand whether systemic medications and biologics, such as dupilumab—a monoclonal antibody that binds to an inflammatory molecule, IL-4 receptor alfa, and inhibits the inflammatory response that leads to rashes and itching from atopic dermatitis/eczema—may have a positive or negative impact on COVID-19 responses in patients who have the disease.
08-Jul-2020 02:05:19 PM EDT

“While these are early data, we have a high degree of confidence in the results, since similar observations on the antiviral activity of these drugs arose from work done independently at both Mount Sinai and Institut Pasteur. Research at this speed and magnitude could only have been accomplished through a collaborative effort from several scientists at multiple institutions, each bringing unique but complementary skill sets towards a common research goal”

- Nature Publication Presents New ‘Blueprint’ Revealing How SARS-CoV-2 Virus Hijacks Human Cells

“I think it’s great trying to come out with a pan coronavirus vaccine or at least a SARS – pan SARS vaccine but there is also another thing that we can think of. If a vaccine that is based on the – whatever antigen we have against the spike of SARS CoV-2 finally is being found to be successful. It will not be very complicated to add to this vaccine a second antigen that is based on the same antigen.”

- Newswise Live Expert Panel for May 14, 2020: Vaccine and Treatment Leaders for COVID-19

“We know that the majority of the transmission comes from viruses that replicate in the upper respiratory tract. But the severe cases are related to the replication of the virus in the lower respiratory tract, in the lungs, where you can get pneumonia, the problems that they give you at the end with the severe disease. So, in order to prevent disease by vaccination, by antibodies, you need antibodies in the lower respiratory tract, which they have access to through the blood.”

- Newswise Live Expert Panel for May 14, 2020: Vaccine and Treatment Leaders for COVID-19

Available for logged-in users onlyLogin HereorRegister
close
0.07471